Mullen Elizabeth A, Chi Yueh-Yun, Hibbitts Emily, Anderson James R, Steacy Katarina J, Geller James I, Green Daniel M, Khanna Geetika, Malogolowkin Marcio H, Grundy Paul E, Fernandez Conrad V, Dome Jeffrey S
Elizabeth A. Mullen, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Yueh-Yun Chi and Emily Hibbitts, University of Florida, Gainesville, FL; James R. Anderson, Merck Research Laboratories, North Wales, PA; Katarina J. Steacy, University of Maryland Medical Center, Baltimore, MD; James I. Geller, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Daniel M. Green, St Jude Children's Research Hospital, Memphis, TN; Geetika Khanna, Washington University School of Medicine, St Louis, MO; Marcio H. Malogolowkin, University of California at Davis Comprehensive Cancer Center, Sacramento, CA; Paul E. Grundy, Stollery Children's Hospital, University of Alberta, Alberta; Conrad V. Fernandez, IWK Health Center, Dalhousie University Halifax, Nova Scotia, Canada; and Jeffrey S. Dome, Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC.
J Clin Oncol. 2018 Oct 18;36(34):JCO1800076. doi: 10.1200/JCO.18.00076.
The use of computed tomography (CT) for routine surveillance to detect recurrence in patients with Wilms tumor (WT) has increased in recent years. The utility of CT, despite increased risk and cost, to improve outcome for these patients is unknown. We conducted a retrospective analysis with patients enrolled in the fifth National Wilms Tumor Study (NWTS-5) to determine if surveillance with CT correlates with improved overall survival (OS) after recurrence compared with chest x-ray (CXR) and abdominal ultrasound (US).
Overall, 281 patients with recurrent unilateral favorable-histology WT were reviewed to assess how WT recurrence was detected: sign/symptoms (SS), surveillance imaging (SI) with CT scan, or SI with CXR/US.
The estimated 5-year OS rate after relapse was 67% (95% CI, 61% to 72%). Twenty-five percent of recurrences were detected with SS; 48.5%, with CXR/US; and 26.5%, with CT. Patients with SS had a 5-year OS rate of 59% (95% CI, 46% to 72%) compared with 70% (95% CI, 63% to 77%; P = .23) for those detected by SI. Recurrences detected by CT had a shorter median time from diagnosis to recurrence (0.60 years) compared with SS (0.91 years) or CXR/US (0.86 years; P = .003). For recurrences detected by SI, more tumor foci at relapse ( P < .001) and size of the largest focus greater than 2 cm ( P = .02) were associated with inferior OS. However, there was no difference in OS after relapse when recurrence was detected by CT versus CXR/US (5-year OS rate, 65% v 73%; P = .20).
In patients with favorable-histology WT, elimination of CT scans from surveillance programs is unlikely to compromise survival but would result in substantial reduction in radiation exposure and health care costs.
近年来,计算机断层扫描(CT)在肾母细胞瘤(WT)患者常规监测以检测复发方面的应用有所增加。尽管存在风险增加和成本上升的问题,但CT对改善这些患者预后的效用尚不清楚。我们对参加第五届全国肾母细胞瘤研究(NWTS - 5)的患者进行了一项回顾性分析,以确定与胸部X线(CXR)和腹部超声(US)相比,CT监测是否与复发后总体生存率(OS)的提高相关。
总体而言,对281例复发性单侧组织学类型良好的WT患者进行了回顾,以评估WT复发是如何被检测到的:体征/症状(SS)、CT扫描监测成像(SI)或CXR/US监测成像(SI)。
复发后的估计5年OS率为67%(95%CI,61%至72%)。25%的复发通过SS检测到;48.5%通过CXR/US检测到;26.5%通过CT检测到。有SS的患者5年OS率为59%(95%CI,46%至72%),而通过SI检测到复发的患者为70%(95%CI,63%至77%;P = 0.23)。与SS(0.91年)或CXR/US(0.86年;P = 0.003)相比,通过CT检测到的复发从诊断到复发的中位时间更短(0.60年)。对于通过SI检测到的复发,复发时更多的肿瘤病灶(P < 0.001)和最大病灶尺寸大于2 cm(P = 0.0